Patients with multiple myeloma who are candidates for stem cell transplantation.. Multiple myeloma and malignant plasma cell neoplasms
Conditions
Interventions
Intervention 1: Intervention group: Patients who underwent autologous HSCT receive three tablets of "gluconate zinc" (each tablet containing 30 mg zinc elemental) daily after eating main meals for fir
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Complete response to treatment Lack of underlying disease Do not get any infection in the last three months, including COVID19 Age range 40 to 60 years Patients with a history of multiple myeloma
Exclusion criteria
Exclusion criteria: History of sensitivity to "zinc" oral supplement Serum levels above 200 mg/dl Patients who have taken oral supplements for three months before transplantation. People's unwillingness to collaborate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of genes(Nrf2-INrf2(Keap1)-SOD1,2-NOX1,2) expression. Timepoint: Before hematopoietic stem cell transplantation beginning and 15,30 days after transplantation. Method of measurement: In DNA extracted from peripheral blood mononuclear cells using Real-Time-PCR.;Determination of MDA-NO protein levels. Timepoint: Before hematopoietic stem cell transplantation beginning and 15,30 days after transplantation. Method of measurement: MDA assay by thiobarbituric acid method and NO assay by griess method.;Determination of TNF-a cytokine. Timepoint: Before hematopoietic stem cell transplantation beginning and 15,30 days after transplantation. Method of measurement: Assay of cytokines by ELISA method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNariman Mosaffa
Shahid Beheshti University of Medical Sciences
Outcome results
None listed